Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B43/00—Formation or introduction of functional groups containing nitrogen
  • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention relates to novel amidoheteroaryl aroyl hydrazide ethynes as tyrosine kinase inhibitors, process of preparation thereof, and use of the compounds for preparation of pharmaceutical compositions in the therapeutic treatment of disorders related to tyrosine kinases in humans.
• Protein tyrosine kinases are currently recognized as important molecular targets for drug development in the treatment of several disorders, particularly in the treatment of proliferative disorders. Dysregulation of tyrosine kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth, proliferation and survival.
• One of the key focus areas in anti-TK drug discovery is the design and development of small molecules that can directly inhibit catalytic activity of the kinase by interfering with the binding of ATP or substrates.
• An important advantage of TK-directed therapy is the possibility to perform pharmacodynamic studies that correlate inhibition of the targeted TK in cancer cells with clinical responses to the drug.
• the second generation TK inhibitors in clinic viz. nilotinib and dasatinib have provided additional treatment option to patients who have developed resistance to imatinib, there are certain shortcomings with regard to their side effects.
• the increased potency may be associated with untoward off-target toxicities, which probably relate to their inhibitory activity against a broader range of protein kinases such as Kit, PDGFR and ephrin receptor (EphA2) tyrosine kinases which are directly implicated in haematopoiesis, control of tissue interstitial-fluid pressure and angiogenesis.
• Omacetaxine (homoharringtonine) is approved by the FDA for CML patients with T315I. However, it is an intravenous drug with a non-specific mechanism of action .
• Ariad Compound Ponatinib (AP24534, US 8114874) is also approved by US FDA but has a boxed warning for risk-threatening blood clots and severe narrowing of blood vessels.
• Other drug candidates in clinical phase include the Deciphera compound DCC-2036 (PCT Publication No. WO 2008/046003).
• the present applicant previously reported novel diarylacetylene hydrazides as tyrosine kinase inhibitors published as WO 2012/098416 Al.
• the current invention describes novel amidoheteroaryl aroyl hydrazide ethynes containing compounds which are not only potent inhibitors of Abl tyrosine kinase but also on its mutant versions.
• Ri is selected from -C 3 _ 6 cycloalkyl, -Ci -6 alkyl-NH 2 , -Q_ 6 alkyl-NH(C ! _ 6 alkyl), -C 1-6 alkyl- N(Ci_6 alkyl)2, alkenyl, -Cj,.(, alkynyl, -Ci_6 alkyl, -C(O) heterocyclyl, heterocyclyl-Ci_6 alkyl, -Ci_6 haloalkyl, -NH(C3_6 cycloalkyl) and heterocyclyl wherein heterocyclyl is 5-6 membered non-aromatic ring containing 1 to 2 heteroatom individually selected from N, O or S;
• Rj is optionally substituted with one or more group independently selected from -C 1 -4 alkyl, halogen, CN, NH(d_ 6 alkyl), N(d_ 6 alkyl) 2 , NH 2 and hydroxy;
• R2 and R3 are individually selected from a group of hydrogen, halogen, -C 1 -4 alkyl, -C 1 -4 haloalkyl, heterocyclyl-Ci_4 alkyl and heteroaryl wherein, heterocyclyl is 5-6 membered non- aromatic ring containing 1 to 2 heteroatom independently selected from N, O or S and is unsubstituted or substituted with -C 1 -4 alkyl and heteroaryl is 5-6 membered aromatic ring containing 1 to 2 heteroatom independently selected from N, O or S and is unsubstituted or substituted with -C 1 -4 alkyl.
• the compounds of the present invention are potent inhibitors of Abl tyrosine kinase including its mutants, and can be used for treating the disease which responds to an inhibition of a tyrosine kinase, especially a neoplastic disease.
• cycloalkyl denotes a non-aromatic mono-, or multicyclic ring system of 3 to about 13 carbon atoms.
• Monocyclic rings include include, but are not limited to cylcopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
• Examples of simple multicyclic cycloalkyl groups include perhydronapththyl, perhydroindenyl etc; bridged multicyclic groups include adamantyl and norbornyl etc, and spriromulticyclic groups for e.g., spiro(4,4)non-2-yl. Unless set forth or recited to the contrary, all cycloalkyl groups described or claimed herein may be substituted or unsubstituted.
• alkyl refers to a hydrocarbon chain radical that includes solely carbon and hydrogen atoms in the backbone, either linear or branched, having from one to eight carbon atoms, both inclusive, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, w-propyl, 1-methylethyl (isopropyl), «-butyl, «-pentyl, and 1,1-dimethylethyl (i-butyl).
• Ci_ 6 alkyl refers to an alkyl chain, linear or branched having 1 to 6 carbon atoms, both inclusive. Unless set forth or recited to the contrary, all alkyl groups described or claimed herein may be, substituted or unsubstituted.
• alkenyl refers to a hydrocarbon chain containing from 3 to 6 carbon atoms, both inclusive and including at least one carbon-carbon double bond which is not in the 1 position, and may have (£) or (Z) configuration.
• alkenyl groups include 2- propenyl (allyl), 2-methyl-2-propenyl, and (Z)-2-butenyl. Unless set forth or recited to the contrary, all alkenyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
• alkynyl refers to a hydrocarbyl radical having at least one carbon-carbon triple bond which is not in the 1 position, and having 3 to about 8 carbon atoms, both inclusive (with radicals having 3 to about 6 carbon atoms being preferred).
• Non-limiting examples of alkynyl groups include 2-propynyl and 3-butynyl. Unless set forth or recited to the contrary, all alkynyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
• heterocyclic ring or “heterocyclyl” unless otherwise specified refers to substituted or unsubstituted non-aromatic 5 to 10 membered ring, preferably 5-6 membered ring, which consists of carbon atoms and from one to five heteroatoms selected from nitrogen, oxygen and sulfur.
• the heterocyclic ring radical may be a mono-, bi- or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states.
• heterocyclic ring or heterocyclyl may optionally contain one or more olefinic bond(s).
• heterocyclic ring radicals include, but are not limited to azepinyl, azetidinyl, benzodioxolyl, benzodioxanyl, chromanyl, dioxolanyl, dioxaphospholanyl, isoxazolidinyl, morpholinyl, oxazolinyl, oxazolidinyl, oxadiazolyl, 2- oxopiperazinyl, 2- oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, octahydroindolyl, octahydroisoindolyl, perhydroazepinyl, piperazinyl, 4-piperazinyl, 4-piperazinyl, 4-piperazinyl, 4-piperazinyl,
• heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclyl groups described or claimed herein may be substituted or unsubstituted.
• halogen or halo means fluorine, chlorine, bromine or iodine.
• haloalkyl or haloalkoxy refers to an alkyl or alkoxy group substituted with one or more halogen atoms.
• heteroaryl refers to substituted or unsubstituted 5 to 14 membered aromatic heterocyclic ring radicals with one or more heteroatom(s) independently selected from N, O or S.
• the heteroaryl may be a mono-, bi- or tricyclic ring system.
• the heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
• heteroaryl ring radicals include, but are not limited to oxazolyl, isoxazolyl, imidazolyl, furyl, indolyl, isoindolyl, pyrrolyl, triazolyl, triazinyl, tetrazoyl, thienyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, benzopyranyl, carbazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, naphthyridinyl, pteridinyl, purinyl, quinoxalinyl, quinolinyl, isoquinolinyl, thiadiazolyl,
• Salts of compounds of Formula I are the physiologically acceptable salts.
• Physiologically acceptable salts are particularly suitable for medical applications, due to their greater solubility in water compared with the starting or base compounds.
• Suitable physiologically acceptable acid addition salts of the compounds of the invention may be salts of inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, and the like or of organic acids such as, for example, acetic acid, benzenesulfonic acid, methanesulfonic acid, benzoic acid, citric acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartartic acid, amino acids, such as glutamic acid or aspartic acid, butanedisulfonic acid and the like.
• Ri is selected from -C3-6 cycloalkyl, -Ci-6 alkyl-NH 2 , -Ci-6 alkyl-NH(Ci-6 alkyl), -Ci-6 alkyl- N(Ci_6 alkyl)2, alkenyl, -Ci_6 alkyl, -C 3 _6 alkynyl, -C(O) heterocyclyl, heterocyclyl-Ci_6 alkyl, -Ci_6 haloalkyl, -NH(C 3 _6 cycloalkyl) and heterocyclyl wherein heterocyclyl is 5-6 membered non-aromatic ring containing 1 to 2 heteroatom individually selected from N, O or S;
• Ri is optionally substituted with one or more group independently selected from -C 1 -4 alkyl, halogen, CN, NH(d_ 6 alkyl), N(d_ 6 alkyl) 2 , NH 2 and hydroxy;
• R 2 and R 3 are individually selected from a group of hydrogen, halogen, -Cj_4 alkyl, -C 1 -4 haloalkyl, heterocyclyl-Ci-4 alkyl and heteroaryl wherein, heterocyclyl is 5-6 membered non- aromatic ring containing 1 to 2 heteroatom independently selected from N, O or S and is unsubstituted or substituted with -C 1 -4 alkyl and heteroaryl is 5-6 membered aromatic ring containing 1 to 2 heteroatom independently selected from N, O or S and is unsubstituted or substituted with -C 1 -4 alkyl.
• Ri is -C3-6 cycloalkyl.
• the compound of Formula I is selected from a group comprising:
• Cyclopropanecarboxylic acid [5-(2-methyl-5- ⁇ N'-[3-(4-methylimidazol-l-yl)-5- trifluoromemylbenzoyl]-hydrazinocarbonyl ⁇ phenylethynyl)pyridin-2-yl]amide; l-(5- ⁇ 5-[N'-(2-Chloro-6-methylbenzoyl)hydrazinocarbonyl]-2-methylphenylethynyl ⁇ - pyridin-2-yl)-3-cyclopropylurea;
• Cyclopropanecarboxylic acid [5-(2-methyl-5-[N'-[4-(4-methylpiperazin-l-yl-methyl)-3- trifluoromethylbenzoyl]-hydrazinocarbonyl ⁇ phenylethynyl)pyridin-2-yl]amide;
• the compound of Formula I is selected from a group comprising: Cyclopropanecarboxylic acid (5- ⁇ 5-[N-(2-chloro-6-methylbenzoyl)hydrazinocarbonyl]-2 methyl-phenylethynyl ⁇ -pyridin-2-yl)amide;
• Cyclopropanecarboxylic acid [5-(2-methyl-5- ⁇ N'-[3-(4-methylimidazol- l-yl)-5 trifluoromemylbenzoyl]-hydrazinocarbonyl ⁇ phenylethynyl)pyridin-2-yl]amide;
• Cyclopropanecarboxylic acid [5-(2-methyl-5-[N'-[4-(4-methylpiperazin-l-yl-methyl)-3 trifluoromemylbenzoyl]-hydrazinocarbonyl ⁇ phenylethynyl)pyridin-2-yl]amide;
• the process involves condensation of the hydrazide of Formula III with the diarylacetylenic compound of Formula II, wherein R l 5 R 2 & R3 are as previously defined for compound of Formula I, and L is a leaving group.
• the condensation reaction is carried out in the presence of an inert base and/or a suitable catalyst in an inert solvent.
• the compound of the Formula II in activated form is especially an acid halide, an ester an anhydride or a cyclic imide.
• esters of Formula II can be selected from, for example vinyl esters obtainable, for example, by transesterification of a corresponding ester with vinyl acetate, carbamoylvinyl esters or by treatment with a C 2 -5 alkoxyacetylene.
• active esters are of the amidino type, such as N,N'-disubstituted amidino esters (obtainable, for example, by treatment of the corresponding acid with a suitable N,N'-disubstituted carbodiimide, for example, N,N'- dicyclohexylcarbodiimide), or N,N'-disubstituted amidino esters (obtainable, for example, treatment of the corresponding acid with N,N-disubstituted cyanamide), suitable aryl esters, especially phenyl esters suitably substituted by electron-attracting substituents (obtainable, for example, by treatment of the corresponding acid with a suitably substituted phenol, for example, 4-nitrophenol, 2,4,5-trichlorophenol, or 2,3,4,5, 6-pentachloro-phenol in the presence of a condensation agent, such as N,N'-dicyclohexylcarbodiimide).
• Suitable active esters include cyanomethyl esters (obtainable, for example, by treatment of the corresponding acid with chloroacetonitrile in the presence of a base), thio esters, especially unsubstituted or substituted, for example nitro-substituted, phenylthio esters (obtainable, for example, by treatment of the corresponding acid with unsubstituted or substituted, for example nitro-substituted, thiophenols, inter alia by the anhydride or carbodiimide method), amino or amido esters (obtainable, for example, by treatment of the corresponding acid with an N-hydroxyamino or N-hydroxyamido compound, for example, N-hydroxysuccinimide, N- hydroxypiperidine, N-hydroxyphthalimide or 1-hydroxybenzotriazole, for example by the anhydride or carbodiimide method).
• cyanomethyl esters obtainable, for example, by treatment of the corresponding acid with chloroacetonitrile in the presence of
• the anhydrides of the compound of Formula II may be formed with carbonic acid semiderivatives, such as corresponding esters, for example carbonic acid alkyl semiesters (obtainable, for example, by treatment of the corresponding acid with haloformic, such as chloroformic, acid); alkyl esters or with a l-alkoxycarbonyl-2-alkoxy-l,2-dihydroquinoline, for example l-alkoxycarbonyl-2-ethoxy-l,2-dihydroquinoline; anhydrides with dihalogenated, especially dichlorinated phosphoric acid (obtainable, for example, by treatment of the corresponding acid with phosphorus oxychloride), or anhydrides with organic acids, such as mixed anhydrides with organic carboxylic acids (obtainable, for example, by treatment of the corresponding acid with an unsubstituted or substituted acyl halide, for example, pivaloyl chloride or trifluoroacetyl chloride).
• Anhydrides may also be with organic sulfonic acids (obtainable, for example, by treatment of a salt, such as an alkali metal salt, of the corresponding acid, with a suitable organic sulfonic acid halide, such as alkane- or aryl-, for example methane- or p-toluenesulfonyl chloride), or with organic phosphonic acids (obtainable, for example, by treatment of the corresponding acid with a suitable organic phosphonic anhydride or phosphonic cyanide).
• organic sulfonic acids obtainable, for example, by treatment of a salt, such as an alkali metal salt, of the corresponding acid, with a suitable organic sulfonic acid halide, such as alkane- or aryl-, for example methane- or p-toluenesulfonyl chloride
• organic phosphonic acids obtainable, for example, by treatment of the corresponding acid with a suitable organic phosphonic anhydride or phosphonic
• Suitable cyclic amides are especially amides with five-membered diazacycles of aromatic character, such as with imidazoles (obtainable, for example, by treatment of the corresponding acid with N,N'-carbonyldiimidazole; imidazolide method), or pyrazoles, for example 3,5-dimethylpyrazole.
• imidazoles obtainable, for example, by treatment of the corresponding acid with N,N'-carbonyldiimidazole; imidazolide method
• pyrazoles for example 3,5-dimethylpyrazole.
• Reactive mixed anhydrides of the acid may also be generated with an organic phosphonic acid in situ by reaction with propylphosphonic anhydride or diethylcyanophosphonate in the presence of suitable base for e.g. triethylamine or 4-(N,N- dimethylamino)pyridine.
• the reaction may be carried out in a manner known per se, the reaction conditions being dependent especially on how the acid group of Formula II has been activated, usually in the presence of a suitable solvent or diluent or of a mixture thereof and, if necessary, in the presence of a condensation agent.
• Customary condensation agents are, for example, carbodiimides such as N,N'-diethyl-, N,N'-diisopropyl, N,N'-dicyclohexyl- or N- ethyl-N'-(3-diethylaminopropyl)-carbodiimide; suitable carbonyl compounds, for example carbonyldiimidazole, or 1,2-oxazolium compounds, for example 2-ethyl-5-phenyl-l,2- oxazolium 3 '-sulfonate and 2-teri-butyl-5-methyl-isoxazolium perchlorate, or a suitable acylamino compound, for example, 2-ethoxy-l-ethoxycarbonyl-l,2-dihydroquinoline.
• carbodiimides such as N,N'-diethyl-, N,N'-diisopropyl, N,N'-dicyclohexyl- or N-
• the bases normally used for aiding the condensation are either inorganic bases such as sodium or potassium carbonate, or organic bases, such as pyridine, triethyamine, N,N- diisopropylethylamine or 4-(dimethylamino)pyridine.
• inorganic bases such as sodium or potassium carbonate
• organic bases such as pyridine, triethyamine, N,N- diisopropylethylamine or 4-(dimethylamino)pyridine.
• the preparation of compounds of Formula I in the present invention can be performed by reacting compounds of Formula IV with the compounds of Formula V, Scheme 2, using similar condensation methods as described above (for Scheme 1); wherein Rj, I3 ⁇ 4, R3
• the compounds of Formula II can be prepared by methods known in the literature. Suitable approaches for the preparation of the compounds for Formula II are provided in Scheme 5.
• the ethynyl moiety of pyridine of Formula VIII is coupled with phenyl ring of Formula IX, or the ethynyl moiety of phenyl ring of Formula VII is coupled with pyridine ring of Formula VI; wherein 'W represents a leaving group like OTf, CI, Br or I, preferably Br or I; L represent OH or O-alkyl.
• the coupling reaction can be performed using well known prior art methods, such as metal catalyzed coupling reactions, for example a palladium catalyzed Sonogashira coupling reaction (refer Malleron, J-L., Fiaud, J-C, Legros, J-Y. Handbook of Palladium Catalyzed Organic Reactions, San Diego: Academic Press, 1997).
• the compound of Formula II is prepared from the vicinal dihalo compound of Formula Ila (where Z represents halo) by tandem dehydrohalogenations.
• the compounds of Formula X & Formula XI can be conveniently prepared by acylation of the hydrazide of Formula III with compounds of Formula VII & Formula IX, respectively, as shown in Scheme 7; wherein L, W, X, Rj, R2 and R3 are as previously defined.
• the compounds of Formula I can also be prepared by acylation of the amine of Formula XII as shown in Scheme 8.
• the compounds of the present invention can be used to treat disorders mediated by tyrosine kinases.
• the following examples serve to illustrate the invention without limiting the invention in its scope. The methods of preparing some of the starting compounds used in the examples are described as reference examples.
• K562/U937 cells (2x104 per well) were incubated with the test compounds/vehicle in a total volume of 200 ⁇ of media at 37oC with 5% C02. On day 4, 20 ⁇ MTT 5mg/ml was added and the cells were incubated for 4-5hours followed by addition of ⁇ ⁇ of 10% SDS prepared in 0.06 ⁇ HC1. The cells were incubated overnight at 37oC with 5% C02. On Day 5 the optical density was measured at 570nm with 630nm as reference wavelength. The optical density in the vehicle treated wells was compared with that of the test compound treated wells.
• mutated Abl (T315I) (human) (5-10 mU) is incubated with 8 mM MOPS pH7.0, 0.2 mM EDTA, 50 ⁇ EAIYAAPFAKKK, lOmM Mg(OAc)2 and [ ⁇ -33 ⁇ - ⁇ ] [specific activity approx. 500 cpm/pmol, concentration as required).
• the reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 5 of a 3% phosphoric acid solution. 10 of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.
• the compounds of Formula I showed good inhibitory action on the mutated Abl T315I cell line.
• Activity data on the mutated Abl T315I cell line for some representative compound is provided in Table-3.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pyridine Compounds (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=57319598

Family Applications (1)

Country Status (13)

Cited By (3)

Families Citing this family (1)

Citations (2)

Family Cites Families (2)

• 2016
  • 2016-05-18 US US15/574,967 patent/US10150733B2/en active Active
  • 2016-05-18 CN CN201680028615.2A patent/CN107709300A/zh not_active Withdrawn
  • 2016-05-18 EP EP16796030.1A patent/EP3297991B1/en active Active
  • 2016-05-18 WO PCT/IN2016/050142 patent/WO2016185490A1/en not_active Ceased
  • 2016-05-18 JP JP2017560135A patent/JP6689887B2/ja not_active Expired - Fee Related
  • 2016-05-18 ES ES16796030T patent/ES2774501T3/es active Active
  • 2016-05-18 CA CA2985161A patent/CA2985161A1/en not_active Abandoned
  • 2016-05-18 AU AU2016263311A patent/AU2016263311A1/en not_active Abandoned
  • 2016-05-18 KR KR1020177033739A patent/KR20180011772A/ko not_active Withdrawn
  • 2016-05-18 MX MX2017014752A patent/MX2017014752A/es unknown
  • 2016-05-18 BR BR112017024633A patent/BR112017024633A2/pt not_active Application Discontinuation
  • 2016-05-18 EA EA201792445A patent/EA032697B1/ru not_active IP Right Cessation
• 2017
  • 2017-11-13 ZA ZA2017/07664A patent/ZA201707664B/en unknown

Patent Citations (2)

Also Published As

Similar Documents

Legal Events